Matinas biopharma holdings, inc. (MTNB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Contract research revenue

-

-

-

0

-

-

-

209

164

149

104

59

14

0

0

59

136

194

194

0

0

-

0

-

-

-

-

-

-

Costs and Expenses:
Contract Research Revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Research and development

13,006

11,234

9,507

8,215

6,909

6,787

7,393

8,027

8,819

9,010

8,260

7,082

5,410

3,947

4,009

4,053

4,765

5,292

5,596

5,786

5,550

5,175

3,988

3,663

2,785

1,761

0

0

0

General and administrative

8,247

7,776

7,934

7,619

7,809

7,978

7,881

7,746

7,481

7,641

6,280

5,840

5,111

4,309

4,465

4,805

4,951

4,813

5,037

5,233

5,412

5,289

4,970

4,142

2,943

1,950

0

0

0

Total costs and expenses

21,254

19,010

17,441

15,834

14,718

14,766

15,275

15,774

16,300

16,652

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,475

8,858

9,717

-

10,633

11,020

10,962

10,464

8,958

7,806

5,729

3,712

0

0

0

Loss from operations

-21,164

-18,921

-17,351

-15,744

-14,628

-14,646

-15,110

-15,564

-16,135

-16,502

-14,436

-12,862

-10,506

-8,257

-8,475

-8,798

-9,580

-9,911

-10,439

-10,885

-10,904

-10,464

0

0

0

-

-

-

-

Sale of New Jersey net operating loss

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income, net

716

541

411

273

98

56

31

26

41

22

10

-5

-18

-16

5

13

13

19

-3

-14

-16

-25

0

0

0

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Other expense, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

Other expense, (income)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Net loss

-18,367

-17,372

-15,426

-13,957

-14,023

-14,083

-14,084

-14,543

-15,100

-15,486

-13,750

-12,193

-9,850

-7,598

-7,713

-8,029

-8,809

-9,135

-10,173

-10,630

-10,652

-10,221

-8,978

-7,822

-5,740

-3,713

0

0

0

Preferred stock series A accumulated dividends

-

338

485

587

587

587

587

591

596

608

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock series B accumulated dividends

637

585

524

430

0

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock series B accumulated dividends

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividend to preferred shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inducement charge from exercise of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Convertible preferred stock beneficial conversion feature accreted as a deemed dividend

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

Inducement charge from exercise of warrants

-

-

-

-

-

-

-

-

-

-16,741

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shareholders

-19,197

-18,296

-16,381

-15,074

-15,046

-14,988

-14,868

-15,156

-15,697

-32,836

-30,953

-33,640

-31,144

-11,992

-12,255

0

0

-

0

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shareholders per share - basic and diluted

-0.03

-0.03

-0.03

-0.03

-0.04

-0.03

-0.03

-0.04

-0.05

-0.03

-0.04

-0.04

-0.25

-0.03

-0.11

-0.03

-0.04

-0.03

-0.04

-0.04

-0.07

-0.09

-0.08

-0.08

-0.07

-0.06

-0.10

-0.03

-0.01

Weighted average common shares outstanding:
Basic and diluted

191,671

163,419

156,889

143,104

117,366

110,138

94,697

94,034

93,542

93,470

92,222

91,611

84,595

58,109

57,628

57,593

57,287

57,449

56,970

55,942

35,561

32,246

32,060

32,000

32,000

41,109

14,895

10,000

10,000

Other comprehensive income/(loss), net of tax
Unrealized gain on securities available-for-sale

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other comprehensive income/(loss), net of tax

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss attributable to shareholders

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-